At bit.bio discovery, a CRISPR perturbation screening platform has been developed to query biology within the context of industry-defining hiPSC derived cellular models. The screening platform is applicable across a wide range of biological questions and disease areas due the quality and physiological relevance of said models combined with the inherent rigor of the genomic screening approach. By creating and utilising physiological relevant, pure and consistent human cell types, with matched disease models, bit.bio discovery offers customers an ever expanding opportunity to perform CRISPR screens. Such screens can be used for the discovery and validation of novel drug targets or to elucidate the mechanism of action of drugs.